Misplaced Pages

Daniel Vasella: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 01:44, 18 September 2017 editInternetArchiveBot (talk | contribs)Bots, Pending changes reviewers5,388,432 edits Rescuing 2 sources and tagging 0 as dead. #IABot (v1.5.2)← Previous edit Latest revision as of 06:55, 25 October 2024 edit undo1AmNobody24 (talk | contribs)Edit filter helpers, Extended confirmed users, Pending changes reviewers, Rollbackers22,425 editsm added link(s) to Die Weltwoche (via WP:JWB) 
(37 intermediate revisions by 18 users not shown)
Line 1: Line 1:
{{Infobox person {{Infobox person
|birth_name=Daniel Lucius Vasella
| name = Daniel Vasella | name = Daniel Vasella
| image = Daniel Vasella World Economic Forum 2013.jpg | image = Daniel Vasella World Economic Forum 2013.jpg
| caption = Vasella at the ] in ], 2013 | caption = Vasella in 2013
| birth_date = {{birth date and age|mf=yes|1953|8|15}} | birth_date = {{birth date and age|df=yes|1953|8|15}}
| birth_place = ], ] | birth_place = ], Switzerland
| occupation = Businessman
| occupation = Unemployed, consulting for different companies, Director of Boards
| networth = 300M USD +
| spouse = Anne-Laurence | spouse = Anne-Laurence
| children = 3 | children = 3
| residence = ], ] | alma_mater = ] (])
| alma_mater = ] (]) <br> ] (])
| signature = | signature =
}} }}
⚫ '''Daniel Lucius Vasella''' (born 15 August 1953) is a Swiss medical doctor, author, and executive who was CEO and chairman of the Swiss pharmaceutical company ], the world's fifth largest drug company.<ref name="10BBC">{{cite news|last=Madslien|first=Jorn|title=Profile: Novartis chief Daniel Vasella|url=http://news.bbc.co.uk/2/hi/business/4167921.stm|work=BBC News|date=19 January 2005|access-date=15 May 2013}}</ref><ref>, ], 13 August 2005</ref> During his tenure Novartis shares fell 10%, compared to the industry average.<ref>, Bilanz, 02/2013</ref><ref name=bilanz022013/> In February 2013 Vasella was awarded close to $78 million in a "]" <ref>, ], 17 February 2013</ref>


⚫ In November 2014, Vasella was elected as a member of the board of directors at XBiotech, Inc, a biopharmaceutical company located in Austin, Texas, that focuses on the discovery and commercialization of a next generation of therapeutic antibodies which harness a human's natural immunity to fight disease. Vasella is an honorary member of the ].<ref name=11AX>{{cite web|title=American Express Company Elects Dr. Daniel Vasella to Board of Directors|url=http://about.americanexpress.com/news/pr/2012/bod-vasella.aspx|publisher=American Express|access-date=15 May 2013|archive-url=https://web.archive.org/web/20121028174240/http://about.americanexpress.com/news/pr/2012/bod-vasella.aspx|archive-date=28 October 2012|url-status=dead}}</ref> In 2004, '']'' magazine named him one of the world's 100 most influential people, and he was chosen as the Most Influential European Business Leader of the Last 25 Years by the readers of the '']''.<ref name=10BBC /><ref name="The 2004 Time 100 : Daniel Vasella">, '']''</ref> He is a former member of the steering committee of the ].<ref>{{Cite web|url=http://www.bilderbergmeetings.org/former-steering-committee-members.html |title=Former Steering Committee Members |work=bilderbergmeetings.org |publisher=] |access-date=2014-02-08 |url-status=dead |archiveurl=https://web.archive.org/web/20140202095633/http://www.bilderbergmeetings.org/former-steering-committee-members.html |archivedate=2014-02-02 }}</ref>
⚫ '''Daniel Lucius Vasella''', M.D. (born 15 August 1953) is a medical doctor, author, and executive who served as CEO and chairman of the ] ] ],<ref>, ], 13 August 2005</ref> the world's fifth largest drug company.<ref name=10BBC>{{cite web|last=Madslien|first=Jorn|title=Profile: Novartis chief Daniel Vasella|url=http://news.bbc.co.uk/2/hi/business/4167921.stm|work=BBC News|accessdate=15 May 2013}}</ref> During his tenure the Novartis shares declined 10%, below the industry.<ref>, Bilanz, 02/2013</ref><ref name=bilanz022013/>

⚫ In November 2014, Vasella was elected as a member of the Board of Directors at , a Biopharmaceutical Company located in Austin, Texas, that focuses on the discovery and commercialization of a next generation of therapeutic antibodies which harness a human's natural immunity to fight disease. Vasella is an honorary member of the ].<ref name=11AX>{{cite web|title=American Express Company Elects Dr. Daniel Vasella to Board of Directors|url=http://about.americanexpress.com/news/pr/2012/bod-vasella.aspx|publisher=American Express|accessdate=15 May 2013}}</ref> In 2004, '']'' magazine named him one of the world’s 100 most influential people, and he was chosen as the Most Influential European Business Leader of the Last 25 Years by the readers of the '']''.<ref name=10BBC /><ref name="The 2004 Time 100 : Daniel Vasella">, '']''</ref> He is a former member of the Steering Committee of the ].<ref>{{Cite web|url=http://www.bilderbergmeetings.org/former-steering-committee-members.html |title=Former Steering Committee Members |work=bilderbergmeetings.org |publisher=] |accessdate=2014-02-08 |deadurl=yes |archiveurl=https://web.archive.org/web/20140202095633/http://www.bilderbergmeetings.org/former-steering-committee-members.html |archivedate=2014-02-02 |df= }}</ref>


==Early life and education== ==Early life and education==


Vasella was born in Fribourg, Switzerland, in 1953.<ref name=3AL></ref> His father was a history professor at the local university, and his mother was a housewife. His desire to become a doctor began during his childhood, which was marked by several tragedies.<ref name=10BBC /><ref name=11AX /> At eight years old, he contracted ] and ] and spent nearly a year in hospitals.<ref name=12MCK>{{cite web|title=An interview with Daniel Vasella|url=http://www.mckinsey.com/features/leading_in_the_21st_century/daniel_vasella|work=McKinsey & Company|accessdate=15 May 2013}}</ref> When Vasella was 13 years old, his father died from complications of surgery.<ref name=12MCK /> Vasella was born in Fribourg, Switzerland, in 1953.<ref name=3AL>{{cite web|url=https://www.alumni.hbs.edu/awards/Pages/default.aspx?year=2003|title=Alumni Achievement Awards – Alumni – Harvard Business School|author=|date=|website=www.alumni.hbs.edu|access-date=30 January 2019}}</ref> His father was a history professor at the local university, and his mother was a housewife. His desire to become a doctor began during his childhood, which was marked by several tragedies.<ref name=10BBC /><ref name=11AX /> At eight years old, he contracted ] and ] and spent nearly a year in hospitals.<ref name=12MCK>{{cite web|title=An interview with Daniel Vasella|url=http://www.mckinsey.com/features/leading_in_the_21st_century/daniel_vasella|work=McKinsey & Company|access-date=15 May 2013|archive-date=28 December 2012|archive-url=https://web.archive.org/web/20121228164053/http://www.mckinsey.com/Features/Leading_in_the_21st_century/daniel_vasella|url-status=dead}}</ref> When Vasella was 13 years old, his father died from complications of surgery.<ref name=12MCK />


Vasella obtained his M.D. in 1980 from the ] in Switzerland.<ref name=3AL /> He completed his residency at the University Hospital in Bern and the city hospital in Zurich, before returning to Bern as chief resident.<ref name=10BBC /><ref name=3AL /> In 1988, he changed career paths, working in the United States as a pharmaceutical sales representative and in ]. In 1989, he completed the Program for Management Development at ].<ref name=10BBC /><ref name=3AL /> Vasella was awarded an honorary doctorate for medicine by the ] in 2002.<ref name=10BBC /><ref name=11AX /> Vasella obtained his M.D. in 1980 from the ] in Switzerland.<ref name=3AL /> He completed his residency at the University Hospital in Bern and the city hospital in Zurich, before returning to Bern as chief resident.<ref name=10BBC /><ref name=3AL /> In 1988, he changed career paths, working in the United States as a pharmaceutical sales representative and in ]. In 1989, he completed the Program for Management Development at ].<ref name=10BBC /><ref name=3AL /> Vasella was awarded an honorary doctorate for medicine by the ] in 2002.<ref name=10BBC /><ref name=11AX />
Line 27: Line 23:
==Career== ==Career==


Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, ]. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the Group Executive Committee.<ref name=10BBC /><ref name=9WC>{{cite web |title=Curriculum Vitae: Dr. Daniel Vasella |url=http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |work=WebCite |accessdate=15 May 2013 |deadurl=yes |archiveurl=https://www.webcitation.org/6DtlcoRaH?url=http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |archivedate=January 24, 2013 |df= }}</ref> Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, ]. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the group executive committee.<ref name=10BBC /><ref name=9WC>{{cite web |title=Curriculum Vitae: Dr. Daniel Vasella |url=http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |work=WebCite |access-date=15 May 2013 |url-status=dead |archiveurl=https://web.archive.org/web/20120425135133/http://www.novartis.com/downloads/about-novartis/people/board-of-directors/Biography_Daniel_Vasella_DE.pdf |archivedate=April 25, 2012 }}</ref>


Vasella helped to orchestrate the 1996 merger between Sandoz and ], another Swiss pharmaceutical company.<ref name=10BBC /> The two companies combined to form ]. Vasella was appointed CEO of the combined entity and a member of the Board of Directors. In 1999, he was named Chairman of the Board of Directors.<ref name=10BBC /> Vasella helped to orchestrate the 1996 merger between Sandoz and ], another Swiss pharmaceutical company.<ref name=10BBC /> The two companies combined to form ]. Vasella was appointed CEO of the combined entity and a member of the board of directors. In 1999, he was named chairman of the board of directors.<ref name=10BBC />


In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, ], the Division Head of Novartis Pharmaceuticals at the time. In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, ], the Division Head of Novartis Pharmaceuticals at the time.


In January 2013, Novartis announced that Vasella would be retiring as Chairman of the Board of Directors in February 2013.<ref>'']'': " {{webarchive|url=https://web.archive.org/web/20130127092811/http://www.businessweek.com/news/2013-01-23/novartis-s-vasella-to-resign-bayer-s-reinhardt-returns |date=2013-01-27 }}"</ref> Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013.<ref>''Pharmaceutical Market Europe'': ""</ref> According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the ].<ref>, Aargauer Zeitung, 2013-02-22.</ref><ref>, NZZ, 2013-02-16.</ref><ref name=bilanz022013>, Bilanz, 2013-02-19.</ref> In January 2013, Novartis announced that Vasella would be retiring as chairman of the board of directors in February 2013.<ref>'']'': " {{webarchive|url=https://web.archive.org/web/20130127092811/http://www.businessweek.com/news/2013-01-23/novartis-s-vasella-to-resign-bayer-s-reinhardt-returns |date=2013-01-27 }}"</ref> Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013.<ref>''Pharmaceutical Market Europe'': ""</ref> According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the ].<ref>, Aargauer Zeitung, 2013-02-22.</ref><ref>, NZZ, 2013-02-16.</ref><ref name=bilanz022013>, Bilanz, 2013-02-19.</ref>

==Other activities==
* Numab Therapeutics, Member of the Board of Directors (since 2019)<ref> Numab Therapeutics, press release of October 15, 2019.</ref>
* ], Member of the Global Health Program Advisory Panel (since 2008)<ref> ], press release of February 2008.</ref>


==Writing== ==Writing==
⚫ Vasella authored ''Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History '' (2003), a book about the discovery and development of the breakthrough cancer drug ].<ref name=17AMAZON>{{cite book|last=Vasella Slater|first=Daniel Robert|title=Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History|date=3 June 2003|publisher=Harper Collins |isbn=0060010304}}</ref> The book was co-written with ].

⚫ Vasella authored ''Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History '' (2003), a book about the discovery and development of the breakthrough cancer drug ].<ref name=17AMAZON>{{cite web|last=Vasella Slater|first=Daniel Robert|title=Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History|url=https://www.amazon.com/Magic-Cancer-Bullet-Rewrite-Medical/dp/0060010304|work=Amazon|accessdate=15 May 2013}}</ref> The book was co-written with Robert Slater.


==Personal life== ==Personal life==


Vasella met Anne-Laurence Moret, the niece of former Sandoz CFO, CEO, and chairman Marc Moret, in 1973, and they were married in 1978.<ref name=13WW>{{cite web|title=Blick für die Frau|url=http://www.weltwoche.ch/ausgaben/2003-19/artikel-2003-19-blick-fuer-die-f.html|work=Die Weltwoche|accessdate=15 May 2013}}</ref> Vasella and his wife have two grown sons and a daughter. His older brother, Andrea Vasella, was a professor at the ].<ref name=13WW /> Vasella is a patron of the arts and enjoys skiing and spending time outdoors.<ref name=16BW>{{cite web|title=Daniel Vasella|url=http://www.businessweek.com/stories/2002-01-13/daniel-vasella|work=Bloomberg Businessweek|accessdate=15 May 2013}}</ref> Vasella met Anne-Laurence Moret, the niece of former Sandoz CFO, CEO, and chairman Marc Moret, in 1973, and they were married in 1978.<ref name=13WW>{{cite web|title=Blick für die Frau|url=http://www.weltwoche.ch/ausgaben/2003-19/artikel-2003-19-blick-fuer-die-f.html|work=]|access-date=15 May 2013}}</ref> Vasella and his wife have two sons and a daughter. His older brother, Andrea Vasella, was a professor at the ].<ref name=13WW /> Vasella is a patron of the arts and enjoys skiing and spending time outdoors.<ref name=16BW>{{cite news|title=Daniel Vasella|url=http://www.businessweek.com/stories/2002-01-13/daniel-vasella|archive-url=https://archive.today/20130616134854/http://www.businessweek.com/stories/2002-01-13/daniel-vasella|url-status=dead|archive-date=June 16, 2013|work=Bloomberg Businessweek|date=14 January 2002|access-date=15 May 2013}}</ref>


==Awards and recognition== ==Awards and recognition==


Vasella has received numerous awards for his humanitarian efforts, corporate philanthropy work, and his leadership in the Pharmaceutical industry. They include: Vasella has received numerous awards including:
* 2003: Harvard Alumnus Award<ref name=15HBS>{{cite web|title=Alumni Achievement Awards: Daniel L. Vasella, M.D.|url=http://www.alumni.hbs.edu/awards/2003/vasella.html|publisher=Harvard Business School|accessdate=15 May 2013}}</ref> * 2003: Harvard Alumnus Award<ref name=15HBS>{{cite web|title=Alumni Achievement Awards: Daniel L. Vasella, M.D.|url=http://www.alumni.hbs.edu/awards/2003/vasella.html|publisher=Harvard Business School|access-date=15 May 2013}}</ref>
* 2004: Most Influential European Business Leader of the Last 25 Years by the readers of ''Financial Times''<ref name=10BBC /> * 2004: Most Influential European Business Leader of the Last 25 Years by the readers of ''Financial Times''<ref name=10BBC />
* 2004: ''Time'' magazine: One of the Top 100 Most Influential Personalities<ref name="The 2004 Time 100 : Daniel Vasella"/> * 2004: ''Time'' magazine: One of the Top 100 Most Influential Personalities<ref name="The 2004 Time 100 : Daniel Vasella"/>
* 2004: The Cancer Research Institute’s Oliver R. Grace Award (for Distinguished Service in Advancing Cancer Research)<ref>.</ref> * 2004: The Cancer Research Institute's Oliver R. Grace Award (for Distinguished Service in Advancing Cancer Research)<ref>.</ref>
* ]’s Karl Winnacker Preis<ref name=14UNI>{{cite web|title=Verleihung des Karl-Winnacker-Preises 2007 an Dr. Daniel Vasella |url=http://www.uni-marburg.de/aktuelles/events/einzeltermine2007/2007/winnackerpreis2007 |publisher=Philipps-Universität, Marburg |accessdate=15 May 2013 }}{{dead link|date=December 2016 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> 2007 * ]’s Karl Winnacker Preis<ref name=14UNI>{{cite web|title=Verleihung des Karl-Winnacker-Preises 2007 an Dr. Daniel Vasella |url=http://www.uni-marburg.de/aktuelles/events/einzeltermine2007/2007/winnackerpreis2007 |archive-url=https://archive.today/20130616134759/http://www.uni-marburg.de/aktuelles/events/einzeltermine2007/2007/winnackerpreis2007 |url-status=dead |archive-date=16 June 2013 |publisher=Philipps-Universität, Marburg |access-date=15 May 2013 }}</ref> 2007
* Elected to the American Academy of Arts and Sciences 2008 * Elected to the American Academy of Arts and Sciences, 2008<ref>{{Cite web|url=https://ceojournals.com/business-directory/daniel-vasella/|title=Daniel Vasella – CEO Journals|language=en-GB|access-date=2020-04-15}}</ref>
* GILD Award for Leadership: Warren Bennis Award for Excellence in Leadership 2010 * GILD Award for Leadership: Warren Bennis Award for Excellence in Leadership, 2010{{citation needed|date=April 2019}}


⚫ ==External links==
*
*
*, ] of India, 10 May 2007
*, ], 13 Nov 2007
*, ]
* , ], 15 Nov 2014
==References== ==References==
{{reflist|2}} {{reflist}}

⚫ ==External links==
*{{C-SPAN}} *{{C-SPAN}}


{{Authority control}} {{Authority control}}

{{DEFAULTSORT:Vasella, Daniel}} {{DEFAULTSORT:Vasella, Daniel}}
] ]
] ]
] ]
]
] ]
] ]
] ]
] ]
] ]
]

Latest revision as of 06:55, 25 October 2024

Daniel Vasella
Vasella in 2013
Born (1953-08-15) 15 August 1953 (age 71)
Fribourg, Switzerland
Alma materUniversity of Bern (MD)
OccupationBusinessman
SpouseAnne-Laurence
Children3

Daniel Lucius Vasella (born 15 August 1953) is a Swiss medical doctor, author, and executive who was CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. During his tenure Novartis shares fell 10%, compared to the industry average. In February 2013 Vasella was awarded close to $78 million in a "golden handshake"

In November 2014, Vasella was elected as a member of the board of directors at XBiotech, Inc, a biopharmaceutical company located in Austin, Texas, that focuses on the discovery and commercialization of a next generation of therapeutic antibodies which harness a human's natural immunity to fight disease. Vasella is an honorary member of the American Academy of Arts and Sciences. In 2004, Time magazine named him one of the world's 100 most influential people, and he was chosen as the Most Influential European Business Leader of the Last 25 Years by the readers of the Financial Times. He is a former member of the steering committee of the Bilderberg Group.

Early life and education

Vasella was born in Fribourg, Switzerland, in 1953. His father was a history professor at the local university, and his mother was a housewife. His desire to become a doctor began during his childhood, which was marked by several tragedies. At eight years old, he contracted TB and meningitis and spent nearly a year in hospitals. When Vasella was 13 years old, his father died from complications of surgery.

Vasella obtained his M.D. in 1980 from the University of Bern in Switzerland. He completed his residency at the University Hospital in Bern and the city hospital in Zurich, before returning to Bern as chief resident. In 1988, he changed career paths, working in the United States as a pharmaceutical sales representative and in market research. In 1989, he completed the Program for Management Development at Harvard Business School. Vasella was awarded an honorary doctorate for medicine by the University of Basel in 2002.

Career

Vasella held a number of medical positions in Switzerland before being hired in 1988 by Sandoz Pharmaceutical Corporation, the former U.S. subsidiary of Swiss pharmaceutical company, Sandoz. He remained there until 1992, when he was promoted to CEO of parent company, Sandoz Pharma Ltd., and named a member of the group executive committee.

Vasella helped to orchestrate the 1996 merger between Sandoz and Ciba-Geigy, another Swiss pharmaceutical company. The two companies combined to form Novartis AG. Vasella was appointed CEO of the combined entity and a member of the board of directors. In 1999, he was named chairman of the board of directors.

In January 2010, Vasella decided to step down as CEO. He was replaced by his hand-picked successor, Joseph Jimenez, the Division Head of Novartis Pharmaceuticals at the time.

In January 2013, Novartis announced that Vasella would be retiring as chairman of the board of directors in February 2013. Vasella was named an honorary chairman, to be succeeded by Jörg Reinhard in August 2013. According to the Ethos foundation Vasella earned from 2002 until 2012 312 Mio CHF from Novartis, and for the years before they estimated it to 60 Mio CHF, a total of 421 Mio CHF in 2013. That he should get 72 Mio CHF for a noncompetition clause at the end made him a public figure during the campaign for the Swiss referendum "against rip-off salaries".

Other activities

  • Numab Therapeutics, Member of the Board of Directors (since 2019)
  • Bill & Melinda Gates Foundation, Member of the Global Health Program Advisory Panel (since 2008)

Writing

Vasella authored Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History (2003), a book about the discovery and development of the breakthrough cancer drug Gleevec. The book was co-written with Robert Slater.

Personal life

Vasella met Anne-Laurence Moret, the niece of former Sandoz CFO, CEO, and chairman Marc Moret, in 1973, and they were married in 1978. Vasella and his wife have two sons and a daughter. His older brother, Andrea Vasella, was a professor at the ETH Zurich. Vasella is a patron of the arts and enjoys skiing and spending time outdoors.

Awards and recognition

Vasella has received numerous awards including:

  • 2003: Harvard Alumnus Award
  • 2004: Most Influential European Business Leader of the Last 25 Years by the readers of Financial Times
  • 2004: Time magazine: One of the Top 100 Most Influential Personalities
  • 2004: The Cancer Research Institute's Oliver R. Grace Award (for Distinguished Service in Advancing Cancer Research)
  • University of Marburg’s Karl Winnacker Preis 2007
  • Elected to the American Academy of Arts and Sciences, 2008
  • GILD Award for Leadership: Warren Bennis Award for Excellence in Leadership, 2010

References

  1. ^ Madslien, Jorn (19 January 2005). "Profile: Novartis chief Daniel Vasella". BBC News. Retrieved 15 May 2013.
  2. The Pharmaceutical Horizon Beckons, The New York Times, 13 August 2005
  3. Keiner verdiente mehr., Bilanz, 02/2013
  4. ^ Vasella: Das Ende der Macht, Bilanz, 2013-02-19.
  5. Novartis golden handshake angers shareholders, politicians, Reuters, 17 February 2013
  6. ^ "American Express Company Elects Dr. Daniel Vasella to Board of Directors". American Express. Archived from the original on 28 October 2012. Retrieved 15 May 2013.
  7. ^ The 2004 Time 100 : Daniel Vasella, Time
  8. "Former Steering Committee Members". bilderbergmeetings.org. Bilderberg Group. Archived from the original on 2014-02-02. Retrieved 2014-02-08.
  9. ^ "Alumni Achievement Awards – Alumni – Harvard Business School". www.alumni.hbs.edu. Retrieved 30 January 2019.
  10. ^ "An interview with Daniel Vasella". McKinsey & Company. Archived from the original on 28 December 2012. Retrieved 15 May 2013.
  11. "Curriculum Vitae: Dr. Daniel Vasella" (PDF). WebCite. Archived from the original (PDF) on April 25, 2012. Retrieved 15 May 2013.
  12. Businessweek: "Vasella Quitting Wins Cheers From Novartis’s Investors Archived 2013-01-27 at the Wayback Machine"
  13. Pharmaceutical Market Europe: "Bayer’s Jörg Reinhardt to replace Daniel Vasella as Novartis chair"
  14. Daniel Vasella hat bei Novartis 421 Millionen Franken verdient, Aargauer Zeitung, 2013-02-22.
  15. Vasella verhilft Abzocker-Initiative womöglich zum Sieg, NZZ, 2013-02-16.
  16. Numab appoints Daniel Vasella to Board of Directors Numab Therapeutics, press release of October 15, 2019.
  17. Global Health Program Advisory Panel Announced by Bill & Melinda Gates Foundation Bill & Melinda Gates Foundation, press release of February 2008.
  18. Vasella Slater, Daniel Robert (3 June 2003). Magic Cancer Bullet: How a Tiny Orange Pill May Rewrite Medical History. Harper Collins. ISBN 0060010304.
  19. ^ "Blick für die Frau". Die Weltwoche. Retrieved 15 May 2013.
  20. "Daniel Vasella". Bloomberg Businessweek. 14 January 2002. Archived from the original on June 16, 2013. Retrieved 15 May 2013.
  21. "Alumni Achievement Awards: Daniel L. Vasella, M.D." Harvard Business School. Retrieved 15 May 2013.
  22. Cancer Research Institute, Oliver R. Grace Award.
  23. "Verleihung des Karl-Winnacker-Preises 2007 an Dr. Daniel Vasella". Philipps-Universität, Marburg. Archived from the original on 16 June 2013. Retrieved 15 May 2013.
  24. "Daniel Vasella – CEO Journals". Retrieved 2020-04-15.

External links

Categories:
Daniel Vasella: Difference between revisions Add topic